Bora CDMO Bora CDMO

X

Find Drugs in Development News & Deals for 2-Deoxy-D-Glucose

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

JP

0

Other Listed Suppliers

SERVICES

0

Details:

2-deoxy-D-glucose (2-DG), reduces the multiplicity of the SARS-CoV-2 virus, alleviates cells from infection-induced cytopathic effect (CPE) and cell death. 2-DG manufactured by Dr. Reddy’s has a purity of 99.5% and is being sold commercially under the brand name 2DG.


Lead Product(s): 2-Deoxy-D-Glucose

Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 28, 2021

  • Deals

Details:

BDR Pharma has inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.


Lead Product(s): 2-Deoxy-D-Glucose

Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: BDR Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 26, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Indian Institute of Chemical Technology, (IICT) and Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Lee Pharma would file the application for getting the approval from DCGI and will manufacture the drug.


Lead Product(s): 2-Deoxy-D-Glucose

Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Lee Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 09, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY